Home
Translational Research in Solid Tumors
Due to medical, economic, and ethical reasons, there is an urgent need to further the development of biomarkers. In the era of molecular-based medicine diagnostic, prognostic, and predictive biomarkers are essential in enhancing disease management. Decoding molecular and genetic alterations using novel high-throughput approaches will enable the translation of results from basic research back to bedside. Our group will focus on the translational research necessary to identify and characterize these biomarkers in solid tumors, primarily emphasizing the cancers of the prostate and lung. Our recent discovery of recurrent TMPRSS2-ETS gene fusions in patients with aggressive prostate cancer is now leading to the development of a commercial test by Ventana Medical Systems.
The funding of our laboratory is provided by the Emmy-Noether-Program of the DFG (German Research Foundation) and by the Rudolf Becker Foundation.
(Photographer: Michael Godehardt Fotodesign, Bochum. )